Next 10 |
home / stock / bovnf / bovnf news
The two poster presentations will report - first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm combination data from the Phase 1/2a study with BI-1206 in combin...
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV) "During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahe...
LUND, SWEDEN / ACCESSWIRE / April 4, 2024 / BioInvent International AB (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2023 has been pu...
Agreement covers Phase 1/2a trial with TNFR2 agonist antibody BI-1910 First data from BI-1910 single agent arm expected by YE 2024 LUND, SWEDEN / ACCESSWIRE / April 2, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the di...
LUND, SE / ACCESSWIRE / February 20, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the year-end report 2023 at 2:00 pm on February 22. The report will be published at 8:00 am CET the same day. BioInvent's ...
LUND, SWEDEN / ACCESSWIRE / February 9, 2024 / BioInvent International (STO:BINV) Clinical supply agreement with AstraZeneca to support Phase 1/2a BI-1206 combination study BI-1206 to be evaluated in combination with Calquence® and rituximab in Phase 1/2a trial in non-Hodgkin's lympho...
Full rights returned following Exelixis' corporate restructuring announced January 07, 2024 Collaboration generated novel targets and antibodies for use in immuno-oncology therapeutics LUND, SWEDEN / ACCESSWIRE / January 12, 2024 / BioInvent International (STO:BINV) BioInvent Internati...
Data from seven different clinical studies expected throughout the year, including combination data for the two lead programs BI-1808 and BI-1206 in H1/mid-2024 Well-financed with 1358 SEK million (~USD 132M), as of September 30, 2023 LUND, SE / ACCESSWIRE / January 4, 2024 / BioInvent ...
LUND, SWEDEN / ACCESSWIRE / December 5, 2023 / BioInvent International (STO:BINV) Phase 1 data from 18 patients treated with BI-1607 in combination with trastuzumab presented at San Antonio Breast Cancer Symposium BI-1607 well tolerated with no serious adverse events, at doses of 75-900mg...
Trial investigates BI-1910 as single agent and in combination with pembrolizumab Exploratory expansion cohorts planned in hepatocellular carcinoma and non-small cell lung cancer BioInvent now has five drug candidates in six clinical trials, reflecting productivity of technology platform...
News, Short Squeeze, Breakout and More Instantly...
Bioinvent Ab Company Name:
BOVNF Stock Symbol:
OTCMKTS Market:
The two poster presentations will report - first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm combination data from the Phase 1/2a study with BI-1206 in combin...
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV) "During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahe...
LUND, SWEDEN / ACCESSWIRE / April 4, 2024 / BioInvent International AB (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2023 has been pu...